| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/IAE.0B013E318206D18C |
| P698 | PubMed publication ID | 21487341 |
| P50 | author | Scott M Whitcup | Q96337420 |
| P2093 | author name string | Xiao-Yan Li | |
| Sunil Gupta | |||
| Homayoun Tabandeh | |||
| David S Boyer | |||
| Sunil S Patel | |||
| David Faber | |||
| Charlie C Liu | |||
| Jean Lou | |||
| Ozurdex CHAMPLAIN Study Group | |||
| P433 | issue | 5 | |
| P921 | main subject | patient | Q181600 |
| dexamethasone | Q422252 | ||
| diabetic macular edema | Q18558081 | ||
| P304 | page(s) | 915-923 | |
| P577 | publication date | 2011-05-01 | |
| P1433 | published in | Retina | Q15753094 |
| P1476 | title | Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients | |
| P478 | volume | 31 |
| Q41496512 | "Magic Bullet": Eccentric Macular Hole as a Complication from Dexamethasone Implant Insertion |
| Q55384382 | A meta-analysis of the effect of a dexamethasone intravitreal implant versus intravitreal anti-vascular endothelial growth factor treatment for diabetic macular edema. |
| Q27008325 | A review of therapies for diabetic macular oedema and rationale for combination therapy |
| Q34252617 | Adult coats' disease successfully managed with the dexamethasone intravitreal implant (ozurdex®) combined with retinal photocoagulation. |
| Q42725451 | Anatomic and pharmacokinetic properties of intravitreal bevacizumab and ranibizumab after vitrectomy and lensectomy |
| Q24658545 | Anatomical effects of dexamethasone intravitreal implant in diabetic macular oedema: a pooled analysis of 3-year phase III trials |
| Q24187587 | Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema |
| Q54115470 | Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema. |
| Q38938500 | Clinical Applications of Dexamethasone for Aged Eyes. |
| Q31146864 | Clinical trials on corticosteroids for diabetic macular edema |
| Q36341458 | Clinical utility of intravitreal fluocinolone acetonide (Iluvien®) implant in the management of patients with chronic diabetic macular edema: a review of the current literature |
| Q89425254 | Comparison of early dexamethasone retreatment versus standard dexamethasone regimen combined with PRN ranibizumab in diabetic macular edema |
| Q55116052 | Comparison of the Effect of Intravitreal Dexamethasone Implant in Vitrectomized and Nonvitrectomized Eyes for the Treatment of Diabetic Macular Edema. |
| Q38261106 | Complications of intravitreal injections in patients with diabetes |
| Q41007892 | Contralateral eye-to-eye comparison of intravitreal ranibizumab and a sustained-release dexamethasone intravitreal implant in recalcitrant diabetic macular edema |
| Q36409906 | Corticosteroid Treatment in Diabetic Macular Edema |
| Q34267270 | Corticosteroid use for diabetic macular edema: old fad or new trend? |
| Q54498160 | Corticosteroids and Anti-Complement Therapy in Retinal Diseases. |
| Q92671027 | Corticosteroids for Diabetic Macular Edema |
| Q35650268 | Current intravitreal pharmacologic therapies for diabetic macular edema |
| Q39103248 | Current treatment strategies and nanocarrier based approaches for the treatment and management of diabetic retinopathy |
| Q34606190 | Current treatments in diabetic macular oedema: systematic review and meta-analysis |
| Q41544958 | Dexamethasone Intravitreal Implant for Chronic Diabetic Macular Edema Resistant to Intravitreal Bevacizumab Treatment |
| Q92696069 | Dexamethasone implant in the management of diabetic macular edema from clinician's perspective |
| Q35828114 | Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study. |
| Q45760542 | Dexamethasone intravitreal implant in the silicone oil-filled eye for the treatment for recurrent macular oedema associated with ankylosing spondylitis: a case report |
| Q26799423 | Dexamethasone intravitreal implant in the treatment of diabetic macular edema |
| Q59697259 | Diabetic Macular Edema: Options for Adjunct Therapy |
| Q30415630 | Diabetic macular edema: New promising therapies |
| Q37985854 | Diabetic macular edema: current and emerging therapies |
| Q34091784 | Diabetic macular edema: new trends in management |
| Q96172012 | Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group |
| Q58704843 | Early Retinal and Choroidal Coat Thickness Changes after Intravitreal Dexamethasone Implant Injection for Diabetic Macular Edema |
| Q36906893 | Effect of intravitreal dexamethasone implant on retinal and choroidal thickness in refractory diabetic macular oedema after multiple anti-VEGF injections. |
| Q93184605 | Effect of intravitreal dexamethasone solution on the reduction of macular thickness in pseudophakic diabetic patients in a public hospital in Brazil: a randomized clinical trial |
| Q92362068 | Effectiveness of Intravitreal Dexamethasone Implant Treatment for Diabetic Macular Edema in Vitrectomized Eyes |
| Q89002608 | Effectiveness of the Dexamethasone Intravitreal Implant for Treatment of Patients with Diabetic Macular Oedema |
| Q91827671 | Efficacy and Safety of Combined Vitrectomy with Intravitreal Dexamethasone Implant for Advanced Stage Epiretinal Membrane |
| Q36949135 | Efficacy and Safety of a Dexamethasone Implant in Patients with Diabetic Macular Edema at Tertiary Centers in Korea. |
| Q33705718 | Efficacy of 0.2 μg/day fluocinolone acetonide implant (ILUVIEN) in eyes with diabetic macular edema and prior vitrectomy |
| Q85695939 | Efficacy of Ozurdex implant in recalcitrant diabetic macular edema--a single-center experience |
| Q90138907 | Efficacy of intravitreal dexamethasone implant in persistent diabetic macular edema after primary treatment with intravitreal ranibizumab |
| Q36013578 | Elevated Intraocular Pressure After Intravitreal Steroid Injection in Diabetic Macular Edema: Monitoring and Management |
| Q38241679 | Emerging drugs for diabetic macular edema |
| Q58907881 | Emerging pharmacotherapies for diabetic macular edema |
| Q34055040 | Evaluation of pain during intravitreal Ozurdex injections vs. intravitreal bevacizumab injections |
| Q36951463 | Evaluation of the effectiveness and safety of glucocorticoids intravitreal implant therapy in macular edema due to retinal vein occlusion. |
| Q35067102 | Evolving strategies in the management of diabetic retinopathy |
| Q92372970 | Hydrodynamics of Intravitreal Injections into Liquid Vitreous Substitutes |
| Q51823268 | Hydrogel Ring for Topical Drug Delivery to the Ocular Posterior Segment. |
| Q61953703 | Iluvien™ (Fluocinolone Acetonide 0.19 mg Intravitreal Implant) in the Treatment of Diabetic Macular Edema: A Review |
| Q35083575 | Importance of 3-D image reconstruction of spectral-domain OCT on outcome of grid laser photocoagulation for diffuse diabetic macular edema |
| Q37287831 | Intravitreal Corticosteroids in the Management of Diabetic Macular Edema |
| Q42422328 | Intravitreal autologous plasmin as a therapeutic modality for diffuse diabetic macular edema |
| Q47807833 | Intravitreal bevacizumab and dexamethasone implant for treatment of chronic diabetic macular edema |
| Q60911605 | Intravitreal corticosteroid implant vs intravitreal ranibizumab for the treatment of macular edema: a meta-analysis of randomized controlled trials |
| Q26782198 | Intravitreal corticosteroids in diabetic macular edema: Pharmacokinetic considerations |
| Q60910817 | Intravitreal dexamethasone implant Ozurdex® in naïve and refractory patients with different subtypes of diabetic macular edema |
| Q34152161 | Intravitreal dexamethasone implant in patients with persistent diabetic macular edema |
| Q49241521 | Intravitreal dexamethasone implants for diabetic macular edema. |
| Q36906859 | Intravitreal fluocinolone acetonide (Iluvien) for treatment of refractory diabetic macular oedema in vitrectomised eyes |
| Q59101228 | Intravitreal steroids for the treatment of retinal diseases |
| Q27687657 | Liposomes and nanotechnology in drug development: focus on ocular targets |
| Q57288658 | Long-term efficacy and duration of action of dexamethasone implant, in vitrectomised and non-vitrectomised eyes with persistent diabetic macular oedema |
| Q36533886 | Long-term evaluation of patients treated with dexamethasone intravitreal implant for macular edema due to retinal vein occlusion |
| Q60921071 | Long-term probability of intraocular pressure elevation with the intravitreal dexamethasone implant in the real-world |
| Q89710210 | Long-term results of a single injection of intravitreal dexamethasone as initial therapy in diabetic macular edema |
| Q42116625 | Management of macular edema secondary to branch retinal vein occlusion in an eye with prior vitrectomy and lensectomy |
| Q26822476 | Microvascular complications and diabetic retinopathy: recent advances and future implications |
| Q50073381 | New Drugs and New Posterior Delivery Methods in CME. |
| Q38622256 | Nonbiological pharmacotherapies for the treatment of diabetic macular edema |
| Q45939532 | OCULAR HYPERTENSION AFTER INTRAVITREAL DEXAMETHASONE (OZURDEX) SUSTAINED-RELEASE IMPLANT. |
| Q42772219 | Ozurdex (a slow-release dexamethasone implant) in proliferative vitreoretinopathy: study protocol for a randomised controlled trial |
| Q34528134 | Pathophysiology and treatment of diabetic retinopathy |
| Q92671068 | Persistent vitreous hemorrhage after intravitreal injection of dexamethasone intravitreal implant in patients with diabetic macular edema |
| Q26786012 | Perspective on the role of Ozurdex (dexamethasone intravitreal implant) in the management of diabetic macular oedema |
| Q47405816 | Pharmacokinetics of intravitreal anti-VEGF drugs in vitrectomized versus non-vitrectomized eyes. |
| Q37038541 | Preliminary results of an intravitreal dexamethasone implant (Ozurdex®) in patients with persistent diabetic macular edema |
| Q38903822 | Preparation of dexamethasone ophthalmic implants: a comparative study of in vitro release profiles. |
| Q57453653 | Progression of Eales' disease post-partum and long-term follow-up: a case report |
| Q48124651 | Projectile propagation of dexamethasone implant in air- and balanced salt solution-filled vitrectomized eyes |
| Q35862168 | Real-world assessment of intravitreal dexamethasone implant (0.7 mg) in patients with macular edema: the CHROME study |
| Q38603354 | Recent developments in ocular drug delivery |
| Q50198182 | Repeated Dexamethasone Intravitreal Implant for the Treatment of Diabetic Macular Oedema Unresponsive to Anti-VEGF Therapy: Outcome and Predictive SD-OCT Features. |
| Q41789707 | Resolution of Persistent Cystoid Macular Edema due to Central Retinal Vein Occlusion in a Vitrectomized Eye following Intravitreal Implant of Dexamethasone 0.7 mg. |
| Q92671023 | Revisiting pars plana vitrectomy in the primary treatment of diabetic macular edema in the era of pharmacological treatment |
| Q46804586 | Risk Factors for Wound Leakage After Ozurdex Injection |
| Q26775853 | Role of implants in the treatment of diabetic macular edema: focus on the dexamethasone intravitreal implant |
| Q91911025 | Scleral fixation of a dexamethasone intravitreal implant in a case of subluxated bag-intraocular lens complex |
| Q42126619 | Short-term Efficacy of Intravitreal Dexamethasone Implant in Vitrectomized Eyes with Recalcitrant Diabetic Macular Edema and Prior Anti-VEGF Therapy |
| Q35436746 | Short-term safety and efficacy of intravitreal 0.7-mg dexamethasone implants for pseudophakic cystoid macular edema |
| Q42795593 | Spontaneous relocation of a trapped retrolenticular slow-release dexamethasone implant (Ozurdex) in a silicone oil-filled eye of a pseudophakic patient |
| Q35030923 | Steroid differentiation: the safety profile of various steroids on retinal cells in vitro and their implications for clinical use (an American Ophthalmological Society thesis). |
| Q44409274 | Steroid implant in anterior chamber of an aphakic vitrectomized eye. |
| Q34394361 | Successful treatment of neovascular age-related macular degeneration following single bevacizumab failure using aflibercept in a vitrectomized eye |
| Q38177288 | Surgical treatment for macular edema |
| Q38591296 | Sustained-release steroids for the treatment of diabetic macular edema. |
| Q38198098 | The Sustained-Release Dexamethasone Implant: Expanding Indications in Vitreoretinal Disease |
| Q36397620 | The clinical outcomes of surgical management of anterior chamber migration of a dexamethasone implant (Ozurdex®). |
| Q38150855 | The evolving treatment options for diabetic macular edema |
| Q90197758 | The impact of artificial intelligence in the diagnosis and management of glaucoma |
| Q92025135 | The role of steroids in treating diabetic macular oedema in the era of anti-VEGF |
| Q49995786 | The study of intravitreal drug pharmacokinetics: does it matter? and if so, how? |
| Q36280656 | Therapeutic Options in Refractory Diabetic Macular Oedema |
| Q38069093 | Think global--act local: intravitreal drug delivery systems in chronic noninfectious uveitis |
| Q53412660 | Topical dexamethasone γ-cyclodextrin nanoparticle eye drops increase visual acuity and decrease macular thickness in diabetic macular oedema. |
| Q35128723 | Treatment of diabetic macular edema with sustained-release glucocorticoids: intravitreal triamcinolone acetonide, dexamethasone implant, and fluocinolone acetonide implant. |
| Q37303225 | Twelve-Month Follow-Up of Dexamethasone Implants for Macular Edema from Various Diseases in Vitrectomized and Nonvitrectomized Eyes. |
| Q55031783 | Uneventful Anterior Migration of Intravitreal Ozurdex Implant in a Patient with Iris-Sutured Intraocular Lens and Descemet Stripping Automated Endothelial Keratoplasty. |
| Q28074846 | Update on corticosteroids for diabetic macular edema |
| Q26767100 | Updates on the Clinical Trials in Diabetic Macular Edema |
| Q58088003 | Vitreous and intraretinal macular changes in diabetic macular edema with and without tractional components |
| Q37940886 | Wandering Ozurdex(®) implant |
| Q86545128 | [Influence of postoperative oral steroid treatment on retinal sensitivity in patients after macular surgery. A randomized, controlled, clinical trial] |
| Q53634009 | [Intravitreal dexamethasone implant for treatment of persistent postoperative macular edema after vitrectomy]. |
Search more.